Core Viewpoint - The company views artificial intelligence (AI) as a driving force and strategic tool for technological innovation and industrial transformation, emphasizing its importance for future development and productivity enhancement [1] Group 1: AI Integration - The company is actively integrating AI across various stages including breeding, cultivation, manufacturing, research and development, and marketing [1] - It has established four major business platforms and an industrial IoT platform to promote the collaborative application of "smart farms + smart factories + smart markets" [1] Group 2: Future Investments - The company plans to increase investments in digital intelligence and deepen AI applications in areas such as precision breeding, intelligent production, cost reduction, efficiency enhancement, decision optimization, business innovation, and user experience improvement [1] - The goal is to ensure that digital intelligence becomes a core driving force for sustained business growth [1]

格隆汇1月16日丨寿仙谷(603896.SH)在投资者互动平台表示，人工智能（AI）是新一轮科技革新和产业 变革的"驱动力量"与"战略抓手"。公司高度重视以AI为代表的现代信息技术与实体产业的深度融合，并 将其视为驱动公司未来发展、培育新质生产力的核心引擎之一。目前，公司已在育种、栽培、制造、研 发、市场等各个环节进行不同程度的AI应用，通过搭建四大业务中台和工业物联网平台等，推动"智慧 农场+智慧工厂+智慧市场"协同应用。未来，公司将持续加大数智化投入，深化AI在精准育种、智能生 产、降本增效、决策优化、业务创新、用户体验升级等多场景的创新应用，让数智化真正成为业务持续 增长的核心驱动力。 ...

（编辑 王雪儿） 证券日报网讯 1月13日，寿仙谷在互动平台回答投资者提问时表示，公司高度重视市值维护与投资者回 报，始终专注于主业经营、技术创新与产品品质提升，力求以稳健的业绩增长回报投资者信任。目前， 公司已与和君咨询签订《战略陪跑咨询服务合同》，围绕"产业+资本、消费+科技、战略+战役"核心设 计思路，谋划公司战略机会，持续推动市值维护与业绩增长的良性循环。 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2] Core Views - The market performance of the traditional Chinese medicine (TCM) sector has shown a modest increase of 2.89%, which is the smallest among the pharmaceutical sub-sectors due to a lack of short-term catalysts and market style shifts [4][5] - The TCM sector's price-to-earnings (PE) ratio (ttm) is 27.39X, reflecting a 0.76X increase from the previous week, while the price-to-book (PB) ratio (lf) stands at 2.3X, up 0.06X [6] - The national health conference held in January 2026 indicates a positive outlook for the penetration rate of TCM services, suggesting a comprehensive development approach for TCM in various healthcare aspects [8] Summary by Sections Market Performance - The TCM sector's performance is lagging behind other pharmaceutical sub-sectors, with a 12-month relative return of -24% compared to the CSI 300 index [4] - The TCM sector's index closed at 6414.65 points, with a weekly increase of 2.89% [21] Valuation - The TCM sector's PE ratio (ttm) is at 27.39X, with a maximum of 30.26X and a minimum of 24.72X over the past year [6] - The PB ratio (lf) is 2.3X, with a maximum of 2.52X and a minimum of 2.17X in the same period [6] Industry Trends - The TCM material market has seen a slight decline in price index due to reduced market traffic, with a total index of 227.06 points, down 0.6% week-on-week [7] - The national health conference emphasizes the ongoing development of TCM services, which is expected to enhance its integration into the healthcare system [8] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [9] - Specific investment targets include companies with strong R&D capabilities and unique products, as well as those less affected by centralized procurement [11]

证券日报网讯1月8日，寿仙谷（603896）在互动平台回答投资者提问时表示，康寿制药前处理车间已经 完成设备采购安装和车间改造，现正在开展各前处理炮制品种的工艺验证工作，完成后即可申报增项。 ...

证券日报网讯1月8日，寿仙谷（603896）在互动平台回答投资者提问时表示，公司将继续坚守主业，开 拓市场，努力以更好的业绩回报全体投资者的信任与支持。后续，公司将结合实际情况继续推出股东回 馈活动，敬请关注公司公告。 ...

Core Viewpoint - The straw industry in China is deeply integrated with agriculture, energy, chemicals, and building materials, forming various industrial chains that enhance rural employment and farmers' income while creating indirect economic value through the substitution of petrochemical and wood resources [2][10]. Market Policy - The Chinese government has implemented a series of policies to promote comprehensive utilization of straw, including subsidies, market construction, and incentive measures, providing a favorable policy environment for the development of the straw recycling and processing industry [2][10][12]. - Key policies include the "Air Quality Continuous Improvement Action Plan," which emphasizes the comprehensive utilization of straw and the prohibition of burning, aiming to stabilize the comprehensive utilization rate of straw above 86% [12][10]. Utilization Volume and Rate - The comprehensive utilization of straw in China is projected to increase from 555 million tons in 2024 to 647 million tons, with feed usage accounting for approximately 18.4%, raw material and substrate fields about 1.8%, edible fungus substrate around 2.3%, and fuel fields about 8.2% [2][10]. - The comprehensive utilization rate of straw is expected to rise from 77.7% in 2024 to 88.3%, with the market size growing from 147.63 billion yuan to 205.10 billion yuan [2][10]. Industry Chain - The straw industry chain in China consists of three levels: upstream resource supply and equipment manufacturing, midstream processing and technology conversion, and downstream diversified applications, moving towards scale, high value, and intelligence [13][14]. - The upstream includes straw resource sources, collection, storage, and machinery, while the midstream focuses on processing and technology conversion, leading to applications in agriculture, energy, building materials, and environmental protection [13][14]. Related Companies - Listed companies involved in the straw industry include Sierte (002538), Yili Group (600887), Huarui Agriculture (833462.NQ), Xuerong Biological (300511), Shouxiangu (603896), Disen Co. (300335), Changqing Group (002616), Sun Paper (002078), and Shengquan Group (605589) [2].

Core Viewpoint - Shouxiangu is investing in a commercial complex that serves as a key initiative for brand experience and channel innovation, aimed at driving marketing reform [1] Group 1: Company Strategy - The commercial complex is positioned as a multi-dimensional consumption core engine and cultural hub, integrating traditional Chinese medicine, dining, and entertainment [1]

Core Viewpoint - The company, Shouxiangu (603896), aims to deepen its focus on the field of food and medicine homology, emphasizing product innovation and channel expansion to enhance its national brand influence and create long-term value for investors [1] Group 1 - The company will continue to innovate its products in the food and medicine homology sector [1] - The company plans to expand its distribution channels to reach a broader audience [1] - The goal is to enhance the brand's national influence [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 证券代码：603896 | 证券简称：寿仙谷 | | --- | --- | | 债券代码：113660 | 债券简称：寿 转债 22 | | | 公告编号：2026-001 | 浙江寿仙谷医药股份有限公司 关于"寿 22 转债"转股结果暨股份变动的公告 根据《上海证券交易所股票上市规则》等有关法律法规的规定和《浙江寿仙 谷医药股份有限公司公开发行可转换公司债券募集说明书》的约定，"寿 22 转债" 转股期自 2023 年 5 月 23 日至 2028 年 11 月 16 日止（如遇法定节假日或休息日延 至其后的第 1 个工作日；顺延期间付息款项不另计息）。"寿 22 转债"的初始转 股价格为 38.08 元/股；因实施公司 2022 年度权益分派，"寿 22 转债"转股价格 自 2023 年 7 月 4 日由 38.08 元/股调整为 37.65 元/股；因实施公司 2023 年度权益 分派，"寿 22 转债"转股价格自 2024 年 6 月 20 日由 3 ...